Trabectedin in patients with metastatic soft tissue sarcoma: A retrospective single center analysis

Anti-Cancer Drugs

Volumn 24, Issue 7, 2013, Pages 725-730

  Schur, Sophie ^a,b   Lamm, Wolfgang ^a,b   Köstler, Wolfgang J ^a,b   Hoetzenecker, Konrad ^a   Nemecek, Elena ^a   Schwameis, Katrin ^a   Klepetko, Walter ^a   Windhager, Reinhard ^a   Brodowicz, Thomas ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b Arcoma Platform Austria   (Austria)

Author keywords

pulmonary metastasectomy; soft tissue sarcoma; toxicity; trabectedin

Indexed keywords

DEXAMETHASONE; TRABECTEDIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER TOXICITY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; SYSTEMIC THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SARCOMA; TETRAHYDROISOQUINOLINES; YOUNG ADULT;

EID: 84879948014     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283629b9b     Document Type: Article

References (36)

1. Casali PG, Blay JY. ESMO/CONTICANET/EUROBONETconsensus panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5):198-203.
2. Brodowicz T, Amann G, Leithner A, Sztankay A, Kainberger F, Eisterer W, et al. Consensus diagnosis and therapy of soft tissue sarcoma. Wien Klin Wochenschr 2012; 124:85-99.
3. Kane JM, Kraybill WG. Radical operations for soft tissue sarcomas. Surg Oncol Clin N Am 2005; 14:633-648.
4. Cheng EY. Surgical management of sarcomas. Hematol Oncol Clin North Am 2005; 19:451-470.
5. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005; 353:701-711.
6. Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist 2002; 7:348-359.
7. Van der Graaf WTA, Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, et al. Results of a randomized phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group [meeting abstract]. ESMO Congress 2012:LBA2882.
8. Bramwell VH, Anderson D, Charette ML. Sarcoma Disease Site Group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003; 3:CD003293.
9. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20:2824-2831.
10. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004; 22:1706-1712.
11. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25:2755-2763.
12. Van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. EORTC Soft Tissue and Bone Sarcoma Group PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879-1886.
13. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S Le Cesne A, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010; 46:72-83.
14. Hartmann JT, Patel S. New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep 2005; 7:300-306.
15. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996; 35:13303-13309.
16. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001; 19:1248-1255.
17. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480-1490.
18. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890-899.
19. LeCesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576-584.
20. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27:4188-4196.
21. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23:1867-1874.
22. Le Cesne A, Misset JL, Demetri G, Lopez-Martin JA, Blay JY, van Oosterom A, et al. Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (STS): results from a pooled analysis of three pivotal phase II clinical trials (P2CT) and safety profile of a 24h infusion schedule. Eur J Cancer 2001; 37:S34.
23. Lamm W, Amann G, Brodowicz T. Case report of suspected rhabdomyolysis during treatment with trabectedin in a patient with metastatic leiomyosarcoma. Case Rep Oncol 2010; 3:477-479.
24. Le Cesne A, Domont J, Cioffi A, Bonvalot S, Terrier P, Ray-Coquard I, et al. Mapping the literature: role of trabectedin as new chemotherapy option in advanced pretreated soft tissue sarcoma. Drugs Today 2009; 45: 403-421.
25. Verweij J. Other endpoints in screening studies for soft tissue sarcomas. Oncologist 2008; 13:32-40.
26. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 2008; 13:32-40.
27. Van Glabekke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft tissue sarcomas. Eur J Cancer 2002; 38:543-549.
28. Blay JY, Italiano A, Ray-Coquard I, Le Cesne A, Duffaud F, Rios M, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer 2013; 13:64.
29. Banerjee SN, Mitchell S, Al-Muderis O, Pennert K, Propert-Lewis C, Dunlop A, et al. The Royal Marsden Hospital experience of trabectedin in patients with advanced soft tissue sarcoma (STS): toxicity and efficacy in a nonselected group. CTOS Connective Tissue Oncology Society, Annual Meeting; Chicago, IL: 2011. Abstract number 48.
30. Hoiczyk M, Grabellus F, Täger G. Trabectedin in heavily pretreated and elderly metastatic soft tissue sarcomas-a single center experience. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie 30.9-04.10.2011, Basel [abstract]. Onkologie 2011; 34 (Suppl 6):V802.
31. Potter DA, Glenn J, Kinsella T, Glatstein E, Lack EE, Restrepo C, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985; 3:353-366.
32. Smith R, Demmy TL. Pulmonary metastasectomy for soft tissue sarcoma. Surg Oncol Clin N Am 2012; 21:269-286.
33. Treasure T, Fiorentino F, Scarci M, Møller H, Utley M. Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data. BMJ Open 2012; 2:pii: e001736.
34. Treasure T, Utley M. Surgical removal of asymptomatic pulmonary metastases: time for better evidence. BMJ 2013; 346:f824.
35. Gomez J, Lopez-Lazaro L, Guzman C. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. J Clin Oncol 2000; 19:727.
36. Paz-Ares L, Lopez-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2012; 302:729-740.